As part of its €500m (US$569m) investment in its life sciences and healthcare (LSHC) infrastructure in the Asia Pacific region, DHL Supply Chain has opened a dedicated pharmaceutical logistics facility in Singapore.
The €10m (US$11.3m) Pharma Hub at 8 Jurong Pier in Singapore features specialized temperature-controlled zones including ambient (15-25°C) and cold room (2-8°C), ensuring precise storage conditions for sensitive healthcare products.
It is good manufacturing practice compliant with advanced cold chain infrastructure, including airtight loading docks and dedicated anterooms, ensuring uninterrupted temperature stability throughout the logistics process. Plans are in place to enable pharma-related value-added services including redressing activities.
“At DHL Supply Chain, we are committed to supporting the rapidly growing LSHC sector in Asia Pacific where there is a growing demand for transformative healthcare solutions due to longer lifespans, personalized treatments and rising consumer expectations,” explained Javier Bilbao, CEO, DHL Supply Chain Asia Pacific.
“By 2030, the region’s medical market is projected to reach US$138bn, reflecting the critical need for resilient and efficient supply chains. As part of DHL Group’s Strategy 2030, we have invested ahead to strengthen our infrastructure and capabilities, ensuring we can meet the evolving and increasingly complex needs of our customers.
“Our investment goes beyond building warehouses or expanding networks. It is about building a foundation across all our business units that enables faster, more reliable delivery of life-saving medicines and healthcare products,” Bilbao continued.
“In a region where healthcare demand is surging, we enable our customers to focus on innovation and patient care. At the same time, we handle the complexities of supply chain management across all logistics touchpoints – from storage, order fulfillment and distribution to global shipping and last-mile delivery. This is how we deliver real value: by turning challenges into opportunities and ensuring that every link in the healthcare supply chain works seamlessly.”
Globally, DHL Group has announced an investment of €2bn (US$2.2bn) by 2030 to boost integrated healthcare solutions. It also recently acquired Cryopdp, a specialty courier providing end-to-end temperature-controlled solutions and white-glove services designed for the LSHC industry.